New to The Street has signed a six-part media series with Medicus Pharma (MDCX). The comprehensive series is designed to elevate Medicus’ visibility with institutional investors, analysts, and the broader healthcare and life sciences community through a multi-channel media and investor engagement strategy. The engagement will spotlight Medicus Pharma’s clinical progress, management vision, and long-term growth opportunities, delivering consistent, high-quality exposure over the course of the engagement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study
- Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License
- Medicus announces amendment to LifeArc license improving Teverelix profile
- Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones
- Medicus Pharma announces clinical data on Teverelix